A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 333

Sponsor: Janssen Korea, Ltd., Korea

Summary

The purpose of this study is to evaluate how safe Opsynvi (macitentan/tadalafil fixed-dose combination) is in adult participants with pulmonary arterial hypertension under routine clinical practice in Korea. Pulmonary arterial hypertension is a condition where the blood vessels that carry blood from the heart to the lungs become narrowed or stiff.

Eligibility Criteria

Inclusion criteria: * Participants who must be prescribed macitentan/tadalafil fixed dose combination (M/T FDC) based on the locally approved label and the physician's medical judgment * Participants who must sign a participation agreement/ICF allowing source data verification in accordance with local requirements Exclusion criteria: * Participants who have any contraindications to M/T FDC, based on the locally approved label * Participants who currently are participating in other interventional clinical trials

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07890285). StuddyBuddy aggregates publicly available trial information.